Amgen announced it will present at the 2026 Wells Fargo Healthcare Conference on September 10, 2026, featuring top executives including CFO Thomas Dittrich and Chief Medical Officer Paul Burton. The presentation will be webcast live and available for replay for 90 days on Amgen's website, providing investors and the public access to updates on the company's business and pipeline. Amgen is a leading biotech firm known for innovative medicines targeting cancer, heart disease, and other serious conditions, and is part of major stock indices like the Dow Jones Industrial Average and Nasdaq-100. This event offers insight into Amgen's ongoing developments and strategic direction.
Jim Cramer highlights Amgen's drug Repatha as a major growth driver, with sales up 37% to $953 million in Q2 2026. The drug reduces heart attack and stroke risk by 20% and is gaining adoption among cardiologists and primary care doctors. Cramer belie...
Amgen's Repatha (evolocumab) significantly reduced all-cause and cardiovascular death risk by 20% in over 12,000 high-risk patients without previous heart attack or stroke, according to the Phase 3 VESALIUS-CV trial. The benefit emerged after 1.5 yea...
